Page last updated: 2024-11-04

tyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5610
CHEMBL ID11608
CHEBI ID15760
SCHEMBL ID4111
MeSH IDM0022194

Synonyms (178)

Synonym
BIDD:ER0507
BRD-K53893978-001-03-1
[3h]tyramine
[3h]-tyramine
gtpl2148
gtpl2150
4-hydroxyphenylethylamine
p-hydroxyphenethylamine
4-hydroxy-beta-phenylethylamine
p-(2-aminoethyl)phenol
tyramin
CHEBI:15760 ,
beta-(4-hydroxyphenyl)ethylamine
4-hydroxyphenethylamine
p-hydroxyphenylethylamine
smr000059295
wln: z2r dq
p-hydroxy-.beta.-phenethylamine
phenol, 4-(2-aminoethyl)-
tenosin-wirkstoff
p-.beta.-aminoethylphenol
benzeneethanamine, 4-hydroxy-
nsc-249188
phenethylamine, p-hydroxy-
.alpha.-(4-hydroxyphenyl)-.beta.-aminoethane
tyrosamine
systogene
phenol, p-(2-aminoethyl)-
.beta.-(4-hydroxyphenyl)ethylamine
4-hydroxy-.beta.-phenylethylamine
DIVK1C_000918
KBIO1_000918
SGCUT00017
SPECTRUM_001213
SPECTRUM4_001801
p-beta-aminoethylphenol
einecs 200-115-8
beta-hydroxyphenylethylamine
alpha-(4-hydroxyphenyl)-beta-aminoethane
hsdb 2132
brn 1099914
nsc 249188
lopac-t-2879
NCGC00016011-01
BSPBIO_002445
uteramine
p-tyramine
nsc249188
tocosine
2-(4-hydroxyphenyl)ethylamine
4-(2-aminoethyl)phenol
IDI1_000918
LOPAC0_001136
SPECTRUM5_000501
OPREA1_294339
inchi=1/c8h11no/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10h,5-6,9h
C00483
51-67-2
tyramine ,
2-(p-hydroxyphenyl)ethylamine
TO_000085
tyramine, 99%
BPBIO1_001394
NCGC00063825-08
NCGC00063825-04
NCGC00063825-05
NCGC00063825-07
MLS000079096 ,
KBIO2_001693
KBIO2_006829
KBIOSS_001693
KBIO2_004261
KBIOGR_002405
KBIO3_001665
SPBIO_000696
SPECTRUM3_000693
NINDS_000918
SPECTRUM2_000738
SPECTRUM210400
BIOMOL-NT_000075
l-tyramine
NCGC00063825-06
4 hydroxyphenethylamine
AEF ,
tyramine, free base
T-8910
A0302
NCGC00016011-10
chembl11608 ,
cid_5610
bdbm29135
AKOS000156022
BMSE000243
ractopamine hydrochloride suspension impurity, tyramine-
fema no. 4215
2-p-hydroxyphenylethylamine
HMS502N20
FT-0651978
HMS1923C19
NCGC00016011-08
BMSE000891
BMSE000870
unii-x8zc7v0ox3
x8zc7v0ox3 ,
4-13-00-01788 (beilstein handbook reference)
STK531130
dtxcid0023874
cas-51-67-2
tox21_110282
dtxsid2043874 ,
tyramine base
HMS2235J05
S3625
CCG-39684
NCGC00016011-11
NCGC00016011-02
NCGC00016011-04
NCGC00016011-05
NCGC00016011-06
NCGC00016011-03
NCGC00016011-07
NCGC00016011-12
NCGC00016011-09
AM20060645
tyramine [hsdb]
tyramine [vandf]
ractopamine hydrochloride suspension impurity, tyramine- [usp impurity]
tyramine [fhfi]
tyramine [who-dd]
tyramine [mi]
AB00051887-15
BBL027695
SCHEMBL4111
NCGC00016011-14
tox21_110282_1
SY002127
mfcd00008193
2-(4-hydroxy-phenyl)ethylamine
2-(4-hydroxyphenyl)-ethylamine
p-hydroxy-phenylethylamine
4-aminoethylphenol
4-(2-aminoethyl)-phenol
(4-hydroxyphenyl)ethylamine
2-(4-hydroxyphenyl)ethanamine
4-(2-amino-ethyl)-phenol
2-(4'-hydroxyphenyl)ethylamine
p-hydroxy-.beta.-phenylethylamine
T-8911
OPERA_ID_887
DB08841
CS-W007606
tyramine, analytical standard
triton wr1339
tyramine, 98%, fg
tyramine, vetec(tm) reagent grade, 99%
sr-01000075365
SR-01000075365-5
p-hydroxy-b-phenylethylamine
4-hydroxy-benzeneethanamine
p-hydroxy-beta-phenethylamine
p-(2-aminoethyl)-phenol
p-hydroxy-beta-phenylethylamine
a-(4-hydroxyphenyl)-b-aminoethane
alpha.-(4-hydroxyphenyl)-beta-aminoethane
4-(2-aminoethyl)-phenol(thyramin)
b-(4-hydroxyphenyl)ethylamine
4- (2-aminoethyl)-phenol
p-hydroxy-b-phenethylamine
4-hydroxy-b-phenylethylamine
HY-W007606
AS-11671
Q165930
SDCCGSBI-0051103.P003
NCGC00016011-20
HMS3885C17
NCGC00016011-16
EN300-51746
ethoxylated p tert octylphenol formaldehyde polymer; triton wr1339

Research Excerpts

Overview

Tyramine (TYR) is a vasoactive biogenic amine found in food products due to improper storage and poor hygiene. Tyramine is a biogenic trace amine that is generated via the decarboxylation of the amino acid tyrosine.

ExcerptReferenceRelevance
"Tyramine is a ligand for receptors that rapidly activate reproductive development in the newly mated queen-previously reproductively inhibited by the mother queen."( Branched tyramides from males of the harvester ant, Pogonomyrmex badius.
Cartwright, KC; Chinta, SP; Jones, TH; Vander Meer, RK, 2023
)
1.63
"Tyramine is a health-adverse biogenic amine, which can accumulate in fermented foods like cheese by decarboxylation of the free amino acid tyrosine by either starter cultures or resident microbes such as lactic acid bacteria including "( Effects of Sodium Chloride on Tyramine Production in a Fermented Food Model and its Inhibition by Tyrosine-degrading
Anderegg, J; Constancias, F; Meile, L, 2020
)
2.29
"Tyramine (TYR) is a vasoactive biogenic amine found in food products due to improper storage and poor hygiene. "( Solid-state potentiometric sensor for the rapid assay of the biologically active biogenic amine (tyramine) as a marker of food spoilage.
Darwish, HW; Darwish, IA; Draz, ME; Saad, AS, 2021
)
2.28
"Tyramine is an important neurotransmitter, neuromodulator, and neurohormone in insects. "( Neuronal distribution of tyramine and the tyramine receptor AmTAR1 in the honeybee brain.
Grübel, K; Möller, K; Reim, T; Rössler, W; Scheiner, R; Scholl, C; Thamm, M, 2017
)
2.2
"para-Tyramine (p-TA) is a biogenic amine which is involved in multiple neuronal signal transductions. "( Role of cationic drug-sensitive transport systems at the blood-cerebrospinal fluid barrier in para-tyramine elimination from rat brain.
Akanuma, SI; Hosoya, KI; Kubo, Y; Yamazaki, Y, 2018
)
1.21
"Tyramine is a substrate of amine oxidases and also an agonist at trace amine-associated receptors."( Mechanisms of the antilipolytic response of human adipocytes to tyramine, a trace amine present in food.
Belles, C; Carpéné, C; Galitzky, J; Zakaroff-Girard, A, 2018
)
1.44
"Tyramine is a biogenic trace amine that is generated via the decarboxylation of the amino acid tyrosine. "( Food sources and biomolecular targets of tyramine.
Andersen, G; Krautwurst, D; Marcinek, P; Schieberle, P; Sulzinger, N, 2019
)
2.22
"Tyramine is a pharmacological tool for understanding comparative and developmental sympathetic regulation of cardiovascular function, and this indirect sympathomimetic agent causes endogenous neuronal catecholamine release, increasing blood pressure and heart rate."( Development of sympathetic cardiovascular control in embryonic, hatchling, and yearling female American alligator (Alligator mississippiensis).
Crossley, DA; Elsey, RM; Eme, J, 2013
)
1.11
"Tyramine is a biogenic compound derived from the decarboxylation of the amino acid tyrosine, and is therefore present at important concentrations in a broad range of raw and fermented foods. "( Mutagenic products are promoted in the nitrosation of tyramine.
Arenas-Valgañón, J; Calle, E; Casado, J; García-Santos, Mdel P; González-Jiménez, M, 2017
)
2.15
"p-Tyramine is an archetypal member of the endogenous family of monoamines known as trace amines, and is one of the endogenous agonists for trace amine-associated receptor (TAAR)1. "( Pharmacological characterization of a high-affinity p-tyramine transporter in rat brain synaptosomes.
Berry, MD; Gardiner, D; Hart, S; Hunter, S; Pryor, AR, 2016
)
1.4
"Tyramine is an important insect neurotransmitter, which has long been neglected in behavioral studies as it was believed to only act as the metabolic precursor of the better-known amine octopamine."( Learning, gustatory responsiveness and tyramine differences across nurse and forager honeybees.
Barron, AB; Entler, BV; Reim, T; Scheiner, R; Søvik, E; Thamm, M, 2017
)
1.45
"Tyramine (TA) is a biogenic amine in invertebrates. "( Molecular cloning and pharmacological characterization of a Bombyx mori tyramine receptor selectively coupled to intracellular calcium mobilization.
Huang, J; Inoue, N; Kita, T; Ohta, H; Ozoe, F; Ozoe, Y; Takao, H, 2009
)
2.03
"Tyramine is a biogenic trace amine that releases monoamines and is a good substrate for monoamine oxidase (MAO)-A/B. "( The biogenic trace amine tyramine induces a pronounced hydroxyl radical production via a monoamine oxidase dependent mechanism: an in vivo microdialysis study in mouse striatum.
Ferger, B; Schmidt, N, 2004
)
2.07
"Tyramine, which is a substrate for both MAO and SSAO, can also stimulate this process and in that case both MAO and SSAO inhibitors attenuate the effect."( Modelling the roles of MAO and SSAO in glucose transport.
Coonan, AM; Davey, G; Fu, W; McDonald, A; O'Sullivan, J; Olivieri, A; Tipton, K, 2007
)
1.06
"Tyramine was found to be a pure competitive inhibitor of hydrolysis for positively charged substrates with both wild-type butyrylcholinesterase and D70G."( Kinetic analysis of effector modulation of butyrylcholinesterase-catalysed hydrolysis of acetanilides and homologous esters.
Froment, MT; Gillon, E; Lockridge, O; Masson, P; Nachon, F; Schopfer, LM, 2008
)
1.07
"Tyramine is an indirect sympathomimetic agent which causes neuronal release of norepinephrine."( The effect of enalapril on tyramine induced changes in renal function in man.
Lang, CC; Rahman, AR; Struthers, AD, 1995
)
1.31
"Para-tyramine (p-TYM) is a predominant urinary amine in humans, rabbit, rat and dog, and its urinary excretion rate may reflect central nervous system pathophysiology. "( In vivo renal production and tubular secretion of tyramine.
Henry, DP; Van Huysse, JW; Willis, LR, 1995
)
1.06
"Tyramine is an indirect sympathetic agent that causes neuronal release of endogenous norepinephrine."( The differential effects of circulating norepinephrine and neuronally released norepinephrine on sodium excretion in humans.
Balfour, DJ; Lang, CC; Rahman, AR; Struthers, AD, 1993
)
1.01
"Tyramine is an endogenous compound which exists in the brain as a trace amine but is also an exogenous compound which is found in foods such as cheese and wine."( Dopamine formation from tyramine by CYP2D6.
Funae, Y; Hiroi, T; Imaoka, S, 1998
)
1.33

Effects

Tyramine has been proved as a cause of adverse reactions, involving headache, hypertensive crisis and interactions with antidepressive drugs. Tyramine probably has an affinity both for storage sites and for catechol amine receptors in the smooth muscle of the nictitating membrane. The "intrinsic activity," however, being very weak or even absent.

ExcerptReferenceRelevance
"Tyramine probably has an affinity both for storage sites and for catechol amine receptors in the smooth muscle of the nictitating membrane, the "intrinsic activity," however, being very weak or even absent."( THE RESPONSES TO TYRAMINE OF THE NORMAL AND DENERVATED NICTITATING MEMBRANE OF THE CAT: ANALYSIS OF THE MECHANISMS AND SITES OF ACTION.
HAEFELY, W; HUERLIMANN, A; THOENEN, H, 1963
)
1.3
"Tyramine has been recognized to release catecholamines from nerve endings and to trigger hypertensive reaction."( Mechanisms of the antilipolytic response of human adipocytes to tyramine, a trace amine present in food.
Belles, C; Carpéné, C; Galitzky, J; Zakaroff-Girard, A, 2018
)
1.44
"Tyramine has been paid more attention in recent years as a significant metabolite of tyrosine and catecholamine drug and an intermediate of medicinal material and some drugs. "( Three-step biocatalytic reaction using whole cells for efficient production of tyramine from keratin acid hydrolysis wastewater.
Jiao, Q; Liu, J; Liu, Q; Lu, Y; Wei, Y; Wu, S; Zhang, H, 2016
)
2.1
"Tyramine probably has an affinity both for storage sites and for catechol amine receptors in the smooth muscle of the nictitating membrane, the "intrinsic activity," however, being very weak or even absent."( THE RESPONSES TO TYRAMINE OF THE NORMAL AND DENERVATED NICTITATING MEMBRANE OF THE CAT: ANALYSIS OF THE MECHANISMS AND SITES OF ACTION.
HAEFELY, W; HUERLIMANN, A; THOENEN, H, 1963
)
1.3
"Also tyramine has been proved as a cause of adverse reactions, involving headache, hypertensive crisis and interactions with antidepressive drugs, which were observed after consumption of ripening cheeses."( [Level of histamine and tyramine in ripening cheeses].
Fonberg-Broczek, M; Sawilska-Rautenstrauch, D, 1995
)
1.05

Actions

Tyramine did not produce vasoconstriction in denervated vessels, but some constriction was observed when the vessels had been pretreated with noradrenaline or with dopamine or dopa. Meta-tyramine appears to inhibit the synthesis of dopamine. Tyramine caused least increase in contractility.

ExcerptReferenceRelevance
"Tyramine caused an increase in MAP and HR and these effects almost disappeared in reserpinized rats."( Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats.
Andersen, RJ; Jansakul, C; Mulvany, MJ; Praman, S; Williams, DE, 2012
)
1.1
"Tyramine did not cause a release of catechols from the suprarenal glands of the cat."( Effect of denervation and of cocaine on the action of sympathomimetic amines.
STROMBLAD, BC, 1960
)
0.96
"Tyramine did not produce vasoconstriction in denervated vessels, but some constriction was observed when the vessels had been pretreated with noradrenaline or with dopamine or dopa."( Response of normal, denervated, and reserpine-treated arteries to sympathomimetic amines and nicotine in dogs.
JACOBSON, JH; MACMILLAN, WH; SMITH, DJ, 1962
)
0.96
"The tyramine-induced increase in cyclic AMP shared a similar pharmacological profile with the octopamine-induced increase in cyclic AMP."( Evidence for a possible neurotransmitter/neuromodulator role of tyramine on the locust oviducts.
Donini, A; Lange, AB, 2004
)
1.04
"Meta-tyramine appears to inhibit the synthesis of dopamine."( The effects of administration of meta-tyramine and para-tyramine on dopamine and its metabolites in the rat striatum.
McQuade, PS; Wood, PL, 1984
)
0.99
"Tyramine caused least increase in contractility."( Pharmacological analysis of dopamine action on the isolated dog atrium.
Chiba, S, 1975
)
0.98

Treatment

Treatment with tyramine initiated a short-lived, fast contraction followed first by a relaxation then by a subsequent sustained contracture. Tyramine treatment did not increase the number of new foragers, suggesting that octopamine was exerting a specific effect. Co-treatment with tyamine and histamine was associated with a reduced hyperglycemic response.

ExcerptReferenceRelevance
"Tyramine-treated scaffolds with mixed pore sizes seeded with chondrocytes were pressed into three-mm porcine osteochondral defects; tyramine treatment enhanced the adhesion of the small pore size scaffold to osteochondral tissue and increased glycosaminoglycan and collagen type II (Col II) contents, while reducing collagen type X (Col X) production in the cartilage layer."( Osteochondral Tissue Regeneration Using a Tyramine-Modified Bilayered PLGA Scaffold Combined with Articular Chondrocytes in a Porcine Model.
Cheng, WH; Hsu, HC; Lin, TH; Wang, HC; Yeh, ML, 2019
)
1.5
"All tyramine treatments resulted in a decrease of the hyperglycemic responses to an i.p."( Effect of prolonged treatment with tyramine on glucose tolerance in streptozotocin-induced diabetic rats.
Bour, S; Carpéné, C; Marq, P; Monje, MC; Morin, N; Nepveu, F; Prévot, D; Subra, C; Valet, P; Visentin, V, 2003
)
1.08
"Tyramine pretreatment resulted in a smaller infarct size than in untreated controls (AN/AR, 0.16 +/- 0.04 versus 0.41 +/- 0.07; P < .01)."( Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning.
Bankwala, Z; Hale, SL; Kloner, RA, 1994
)
1.01
"Tyramine treatment did not increase the number of new foragers, suggesting that octopamine was exerting a specific effect."( Octopamine influences division of labor in honey bee colonies.
Robinson, GE; Schulz, DJ, 2001
)
1.03
"Co-treatment with tyramine and histamine was associated with a stronger cytotoxic effect than was treatment with either BA or on its own."( The dietary biogenic amines tyramine and histamine show synergistic toxicity towards intestinal cells in culture.
Alvarez, MA; Del Rio, B; Fernandez, M; Ladero, V; Linares, DM; Martin, MC; Redruello, B; Ruas-Madiedo, P, 2017
)
1.07
"treatment with tyramine, which leads to the release of endogenous noradrenaline."( Adrenergic suppression of peripheral blood T cell reactivity in the rat is due to activation of peripheral alpha 2-receptors.
Felsner, P; Hofer, D; Korsatko, W; Porta, S; Rinner, I; Schauenstein, K, 1995
)
0.63
"Treatment with tyramine initiated a short-lived, fast contraction followed first by a relaxation then by a subsequent sustained contracture."( Tyramine-induced release of neuropeptide Y (NPY) in isolated rabbit intestine.
Cheng, JT; Shen, CL, 1986
)
2.05

Toxicity

Tyramine and histamine are the biogenic amines (BA) most commonly found at high concentrations in food. Cytotoxicity assay demonstrated that tyramine/glucose Maillard reaction products (MRPs) were significantly less toxic than that of Tyramine.

ExcerptReferenceRelevance
" These results suggest that T-794 is an effective and particularly safe antidepressant and that it may make an important contribution in the treatment of depressive disorders."( In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
Iwata, H; Katayama, T; Kato, M; Matsuoka, Y; Narita, H; Yamamura, M, 1998
)
0.3
" Side effect profiles were similar for STS and placebo with the exception of application-site reaction, which was observed in 31."( A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam, JD, 2003
)
0.32
"Dissociating glucocorticoid receptor (GR) ligands hold great promise for treating inflammatory disorders since it is assumed that they exert beneficial activities mediated by transrepression but avoid adverse effects of GR action requiring transactivation."( Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.
Hanisch, UK; John, M; Lühder, F; Menzfeld, C; Reichardt, HM; Tischner, D; Tuckermann, JP; van den Brandt, J; Wüst, S, 2009
)
0.35
"CpdA has significant therapeutic potential although adverse effects severely compromise its application in vivo."( Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.
Hanisch, UK; John, M; Lühder, F; Menzfeld, C; Reichardt, HM; Tischner, D; Tuckermann, JP; van den Brandt, J; Wüst, S, 2009
)
0.35
"The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs)."( Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Bodkin, JA; Pae, CU; Patkar, AA; Portland, KB; Thase, ME, 2012
)
0.38
"Deidentified data were obtained on AEs, regardless of causality, as collected and compiled in the pharmaceutical company's adverse event collection systems/databases after the launch of STS in the United States."( Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Bodkin, JA; Pae, CU; Patkar, AA; Portland, KB; Thase, ME, 2012
)
0.38
" According to risk assessment data published by EFSA in 2011, histamine and tyramine are the most toxic biogenic amines and the ones that most affect food safety."( Melatonin is formed during winemaking at safe levels of biogenic amines.
Callejón, RM; Cantos-Villar, E; Garcia-Parrilla, MC; Ordóñez, JL; Rodriguez-Naranjo, MI, 2013
)
0.62
" sakei Al-143 strains possess the best properties to be selected as adequate and safe meat starter cultures."( Technological and safety properties of lactic acid bacteria isolated from Spanish dry-cured sausages.
Carrascosa, AV; Curiel, JA; de las Rivas, B; Landeta, G; Muñoz, R, 2013
)
0.39
"Tyramine and histamine, the most toxic biogenic amines (BA), are often found in high concentrations in certain foods."( Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine.
Alvarez, MA; del Rio, B; Fernandez, M; Ladero, V; Linares, DM; Martin, MC; Redruello, B; Ruas-Madiedo, P, 2016
)
2.1
" The HILIC-ESI-MS/MS based analytical strategy is a useful tool to reveal the relationships between the toxic herb components and the endogenous metabolite profiling in the toxicity investigation of herb medicines."( An analytical strategy to investigate Semen Strychni nephrotoxicity based on simultaneous HILIC-ESI-MS/MS detection of Semen Strychni alkaloids, tyrosine and tyramine in HEK 293t cell lysates.
Bi, K; Chen, X; Gu, L; Hou, P; Liu, Z; Zhang, R, 2016
)
0.63
"Tyramine and histamine are the biogenic amines (BA) most commonly found at high concentrations in food; they may even appear together at toxic concentrations."( The dietary biogenic amines tyramine and histamine show synergistic toxicity towards intestinal cells in culture.
Alvarez, MA; Del Rio, B; Fernandez, M; Ladero, V; Linares, DM; Martin, MC; Redruello, B; Ruas-Madiedo, P, 2017
)
2.19
" Cytotoxicity assay demonstrated that tyramine/glucose Maillard reaction products (MRPs) were significantly less toxic than that of tyramine (p<0."( A study of the tyramine/glucose Maillard reaction: Variables, characterization, cytotoxicity and preliminary application.
Chen, Y; He, X; Hu, S; Jiang, W; Li, S; Liu, Y, 2018
)
1.1
" crispa pediculicidal ointment is safe and effective, having acceptable physicochemical characteristics."( Safety, Efficacy, and Physicochemical Characterization of Tinospora crispa Ointment: A Community-Based Formulation against Pediculus humanus capitis.
Arollado, EC; de Guzman, ALDP; Manalo, RAM; Ponsaran, KMG; Torre, GLTD, 2017
)
0.46
" Nowadays, even 'matured' cheeses are usually safe in healthy-sized portions."( A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.
Gillman, PK, 2018
)
0.7

Pharmacokinetics

amine systemic bioavailability in the presence of toloxatone. tyramine elimination half-life was 0.01 ng/mL. This pharmacodynamic interaction could be explained by an increase in Tyramine systemic Bioavailability.

ExcerptReferenceRelevance
"A series of studies on the pharmacokinetic and pharmacodynamic properties of some tricyclic antidepressants is reviewed."( Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Asberg, M, 1976
)
0.26
" This pharmacodynamic interaction could be explained by an increase in tyramine systemic bioavailability in the presence of toloxatone."( Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.
D'Estanque, J; Ego, D; Funck-Brentano, C; Jaillon, P; Provost, JC; Rovei, V, 1992
)
0.72
" Kinetics of plasma concentration satisfied the concept of a two compartment open system, with an alpha-phase half-life of about 3 mins, and a beta-phase half-life of about 35 mins."( Hordenine: pharmacology, pharmacokinetics and behavioural effects in the horse.
Blake, JW; Chang, SL; Ewing, A; Frank, M; Tai, CL; Tobin, T; Weckman, TJ; Wood, T; Woods, WE, 1990
)
0.28
"A combined pharmacodynamic and pharmacokinetic approach was made to study the pharmacodynamic half-life (Pd1/2) of amitriptyline (AT)."( Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life.
Ghose, K, 1980
)
0.66
" Experiments with lipophilic LMWH tracer bound nonspecifically to rat serum albumin confirmed that the prolonged half-life might in part be due to an increased affinity for albumin."( Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats.
Dempfle, CE; Friedrich, EA; Harenberg, J; Heene, DL; Maier-Borst, W; Peschke, P; Schrenk, HH; Sinn, H; Stehle, G; Wunder, A, 1993
)
0.29
" The method was successfully applied to pharmacokinetic study of hordenine after oral and intravenous administration."( Validated UPLC-MS/MS method for determination of hordenine in rat plasma and its application to pharmacokinetic study.
Geng, P; Huang, X; Ma, J; Wang, S; Wang, X; Wen, C; Yu, L; Zhou, Y, 2015
)
0.42
" In order to quantitatively characterize the potential risk and/or support regulatory decision-making, chronic and acute BA exposure scenarios were developed and simulated with a physiologically based pharmacokinetic model."( Profiling wines in China for the biogenic amines: A nationwide survey and pharmacokinetic fate modelling.
Bogdal, C; Göktaş, RK; Ke, R; Wei, Z; Xiao, R, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"5 g of levodopa daily for up to six months and in 30 patients receiving levodopa (800-1,000 mg) combined with a dopa decarboxylase inhibitor, benserazide (200-250 mg)."( Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Rinne, UK; Siirtola, T; Sonninen, V, 1975
)
0.25
"Multiplex PCR and DNA microarray were combined with tyramide signal amplification (TSA) to develop a reliable method suitable for simultaneous detection of six species of human diarrheal pathogens (Yersinia enterocolitica, Shigella spp, Salmonella typhi, Brucella spp, Vibrio cholera and Escherichia coli O157:H7)."( Simultaneous detection of six human diarrheal pathogens by using DNA microarray combined with tyramide signal amplification.
Chen, S; Jin, D; Liu, Q; Qi, H; Wang, S; Zeng, T, 2008
)
0.35
"  The development of new drugs or compounds to be used alone or in combination with currently available chemotherapeutic agents to improve the treatment of CCA is needed."( Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells.
Budunova, I; Haegeman, G; Junking, M; Panya, A; Rattanaburee, T; Yenchitsomanus, PT, 2020
)
0.56
" Carbon spheres QuEChERS mixed dispersion solid phase extraction combined with HPLC was used for the classification and analysis of batch samples."( Pollution, Exposure and Risk of Biogenic Amines in Canned Sea Fish: Classification of Analytical Methods Based on Carbon Spheres QuEChERS Extraction Combined with HPLC.
Dai, Z; Guo, X; Zhang, W, 2022
)
0.72

Bioavailability

Tyramine challenge studies have demonstrated that it requires. approximately twice the amount of tyramine administered with a meal compared to. administration after a fast to elicit the same effect. The new study provides better answers in a simplified and safer design compared with the classical design in trial simulation.

ExcerptReferenceRelevance
" This pharmacodynamic interaction could be explained by an increase in tyramine systemic bioavailability in the presence of toloxatone."( Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.
D'Estanque, J; Ego, D; Funck-Brentano, C; Jaillon, P; Provost, JC; Rovei, V, 1992
)
0.72
" Relative bioavailability of conjugated tyramine was elevated sixfold by brofaromine and 11."( Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Antonin, KH; Bieck, PR; Firkusny, L; Nilsson, E; Schick, C; Schulz, R; Schwenk, M; Wollmann, H, 1989
)
0.54
" This assay is suitable for studies on the bioavailability of ingested tyramine and should thus have a role in the development of safer monoamine oxidase inhibitor drugs."( High-performance liquid chromatography with amperometric determination of plasma tyramine.
Brown, MJ; Causon, RC, 1984
)
0.73
" The relative bioavailability of p-tyramine after treatment was not significantly different from before treatment, although a tendency to a greater bioavailability was seen with the 12 and 24 mg doses."( Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline.
Dulery, BD; Haegele, KD; Hinze, C; Huebert, ND; Schoun, J; Schwach, V, 1994
)
0.86
" The first order absorption rate constant for each segment was estimated by means of a conventional in situ closed loop method."( Analysis and prediction of absorption profile including hepatic first-pass metabolism of N-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit-absorption model.
Haruta, S; Higaki, K; Iwasaki, N; Kimura, T; Ogawara, KI; Yokoe, JI; Yokoo, Y, 2000
)
0.52
"Tyramine challenge studies have demonstrated that it requires approximately twice the amount of tyramine administered with a meal compared to administration after a fast to elicit the same effect, suggesting a reduction in bioavailability of tyramine when administered with food."( Tyramine pharmacokinetics and reduced bioavailability with food.
Azzaro, AJ; Blob, LF; Kemper, EM; VanDenBerg, CM, 2003
)
3.2
" Both BW 467C60 and BW 392C60 were well absorbed from the alimentary tract."( Adrenergic neurone blockade and other acute effects caused by N-benzyl-N'N"-dimethylguanidine and its ortho-chloro derivative.
BOURA, AL; GREEN, AF, 1963
)
0.24
" Local BH(4) supplementation augments reflex and tyramine-induced VC in aged skin, suggesting that reduced BH(4) bioavailability may contribute to attenuated VC during whole-body cooling."( Local tetrahydrobiopterin administration augments cutaneous vasoconstriction in aged humans.
Holowatz, LA; Kenney, WL; Lang, JA, 2009
)
0.61
" These data are consistent with the concept that reduced bioavailability of BH(4) and/or tyrosine may impair noradrenaline synthesis and contribute to the attenuated vasoconstrictor response in aged skin."( Localized tyrosine or tetrahydrobiopterin supplementation corrects the age-related decline in cutaneous vasoconstriction.
Holowatz, LA; Kenney, WL; Lang, JA, 2010
)
0.36
"Amkamide is a phenolic amide whose analogues were recently reported to have potent mitochondria protective activity, although their bioavailability is still unknown."( Synthesis, HPLC measurement and bioavailability of the phenolic amide amkamide.
Park, JB,
)
0.13
" Bioavailability of tetrahydrobiopterin (BH4), an essential cofactor for catecholamine synthesis, is reduced with aging."( Oral sapropterin augments reflex vasoconstriction in aged human skin through noradrenergic mechanisms.
Alexander, LM; Kenney, WL; Stanhewicz, AE, 2013
)
0.39
" However, the bioavailability of alfrutamide and caffedymine and their effects on cardiovascular diseases (CVDs), particularly via effects on P-selectin expression(PSE) and platelet-leukocyte aggregation (PLA), are unknown."( Bioavailability of Alfrutamide and Caffedymine and Their P-Selectin Suppression and Platelet-Leukocyte Aggregation Mechanisms in Mice.
Park, JB, 2016
)
0.43
"The objective of this study was to investigate the bioavailability of alfrutamide and caffedymine and their effects on PSE and PLA, which are frequently involved in the progression of CVDs."( Bioavailability of Alfrutamide and Caffedymine and Their P-Selectin Suppression and Platelet-Leukocyte Aggregation Mechanisms in Mice.
Park, JB, 2016
)
0.43
" Bioavailability was determined by HPLC analysis of plasma samples from Swiss Webster mice orally administered alfrutamide and caffedymine (10 μg each)."( Bioavailability of Alfrutamide and Caffedymine and Their P-Selectin Suppression and Platelet-Leukocyte Aggregation Mechanisms in Mice.
Park, JB, 2016
)
0.43
"These data show the adequate bioavailability of alfrutamide and caffedymine and their different mechanisms of suppressing PSE and PLA: alfrutamide exerts its effects only via COX inhibition, whereas caffedymine works through both COX inhibition and cAMP amplification."( Bioavailability of Alfrutamide and Caffedymine and Their P-Selectin Suppression and Platelet-Leukocyte Aggregation Mechanisms in Mice.
Park, JB, 2016
)
0.43
" In this regard, information regarding the bioavailability and metabolic disposition of hydroxytyrosol and tyrosol is of most importance to evaluate the impact they may have on human health."( Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol.
Boronat, A; de la Torre, R; Farré, M; Fitó, M; Khymenets, O; Kotronoulas, A; Olesti, E; Pastor, A; Pérez-Mañá, C; Pujadas, M; Rodríguez-Morató, J, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, the high bioavailability may be reduced by the observed efflux transport of hordenine from the bloodstream back into the intestinal lumen and by first pass metabolism in intestinal epithelial cells."( Permeability of dopamine D2 receptor agonist hordenine across the intestinal and blood-brain barrier in vitro.
Behrens, M; Esselen, M; Hahn, M; Humpf, HU; Langer, K; Lindemann, V; Mulac, D, 2022
)
0.72
" By its focus on tyramine bioavailability as the primary concern for novel MAO inhibitors, the new tyramine challenge study provides better answers in a simplified and safer design compared with the classical design in trial simulation, warranting its use in future clinical studies."( Rethinking, reducing, and refining the classical oral tyramine challenge test of monoamine oxidase (MAO) inhibitors.
Constant, J; Hartstra, J; Smith, KL; van Hoogdalem, EJ, 2023
)
1.5

Dosage Studied

The intrarenal distribution of blood flow in the baboon was measured using the 133xenon clearance technique. dose-response curves for the various components of renal blood flow were determined during intra-arterial infusions of noradrenaline; the alpha-adrenergic blocking agent, phenoxybenzamine and tyramine.

ExcerptRelevanceReference
" In the dosage used (100 mg/day) ciclazindol was observed to be a peripheral Na-reuptake blocker with no significant effect on the postsynaptic alpha-receptors."( Antidepressant activity and pharmacological interactions of ciclazindol.
Bailey, J; Coppen, A; Ghose, K; Rama Rao, VA, 1978
)
0.26
" Its effect (in the dosage used) on the tyramine dose--pressor response and NA dose--pressor response tests were less than those of amitryptyline."( Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients.
Coppen, A; Ghose, K; Gupta, R; Lund, J, 1977
)
0.52
" Following each treatment the effect of tyramine was diminished, with a shift to the right in the tyramine dose-response curve."( Influence of nomifensine and desipramine on tyramine pressor responses in healthy volunteers.
McEwen, J, 1977
)
0.79
" The dose-response curves for the two last-mentioned dopamine metabolites closely follow those for MAO A and dopamine-deaminating activity, whether clorgyline or deprenil was used as MAO inhibitor."( Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Delini-Stula, A; Maître, L; Waldmeier, PC, 1976
)
0.26
" Both drugs also shift to the left the dose-response curves for noradrenaline and adrenaline on isolated strips, cocaine being most potent."( Uptake and release of catecholamines in sympathetic nerve fibres in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" The effect of acetylcholine is also significantly potentiated by pretreatment with 6-hydroxydopamine or denervation, but not by reserpine, while the dose-response curve for carbachol is not affected by the specific cholinesterase inhibitor BW 284 C51, denervation or 6-hydroxydopamine."( Uptake and release of catecholamines in sympathetic nerve fibers in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" Dose-response curves show a parallel shift to the right with no change in the maximum response suggesting a competitive atropine-like action."( The action of tetraethyl-ammonium chloride on the response of the rat anococcygeus muscle to motor and inhibitory nerve stimulation and to some drugs.
Gillespie, JS; Tilmisany, AK, 1976
)
0.26
" Droperidol induced a dose-dependent shift of the noradrenaline dose-response curve to the right, but proved to be 20 times less potent than phentolamine."( Effects of droperidol on cardiovascular adrenoceptors.
Göthert, M; Thies, FK; Veth, N, 1976
)
0.26
" The dose-response curve was depressed by pretreatment with reserpine."( [On the mode of action of heptaminol (author's transl)].
Grobecker, H, 1976
)
0.26
" Dose-response graphs for the tyramine pressor effect were shifted to the right during the antidepressant treatment, indicating a blockade of the membrane pump in peripheral sympathetic terminals."( Effect of tricyclic antidepressants and alcohol in psychomotor skills related to driving.
Elonen, E; Linnoila, M; Mäki, M; Mattila, MJ; Seppälä, T, 1975
)
0.54
"The intrarenal distribution of blood flow in the baboon was measured using the 133xenon clearance technique, and dose-response curves for the various components of renal blood flow were determined during intra-arterial infusions of noradrenaline; the alpha-adrenergic blocking agent, phenoxybenzamine; the beta-adrenergic blocking agent, propranolol; and tyramine which causes the release of endogenous NA."( The effect of noradrenaline, adrenergic blocking agents, and tyramine on the intrarenal distribution of blood flow in the baboon.
Bomzon, L; Farr, J; Rosendorff, C; Scriven, DR, 1975
)
0.67
" The sympathetic denervation did not influence the dose-response curve obtained with acetylcholine, supporting the specific nature of the supersensitivity reaction only to the sympathetic transmitter."( Sympathetic innervation of cerebral arteries: prejunctional supersensitivity to norepinephrine after sympathectomy or cocaine treatment.
Aubineau, P; Edvinsson, L; Owman, C; Sercombe, R; Seylaz, J,
)
0.13
" The dose-response curves for the compound 48/80-induced release of endogenous Hi and for the various amines taken up by the cells were compared."( Intracellular distribution of amines taken up by rat mast cells.
Bergendorff, A, 1975
)
0.25
" The effect of ATPase inhibition on the response pattern after repetitive dosing with phenylephrine (PE) and KCl was also determined."( Effects of Na-K-ATPase inhibition on catecholamine reactivity in rat pulmonary artery.
Cutaia, M; Rudio, K, 1992
)
0.28
"3-3 mg/kg); the former effect was not dose dependent (bell-shaped dose-response curve), whereas the latter effect was dose-dependent."( Cardiovascular effects of cocaine in conscious rats: relative significance of central sympathetic stimulation and peripheral neuronal monoamine uptake and release mechanisms.
Goldberg, SR; Schindler, CW; Tella, SR, 1992
)
0.28
" After 1 week, the grafts were harvested and dose-response curves to norepinephrine and tyramine were determined and compared with those of nongrafted saphenous veins and carotid arteries."( Altered responsiveness of saphenous vein grafts to norepinephrine and tyramine: relation to tissue catecholamine stores.
Soliman, AS; Tackett, RL, 1991
)
0.74
" In 5- and 10-day-old animals, prenalterol treatment produced minimal stimulation of PRA and the dose-response curve was essentially flat."( Effects of sympathetic activation on plasma renin activity in the developing rat.
Johnson, AK; Kirby, RF, 1990
)
0.28
" Typically, dosed horses showed a flehmen response and defecated within 60 secs."( Hordenine: pharmacology, pharmacokinetics and behavioural effects in the horse.
Blake, JW; Chang, SL; Ewing, A; Frank, M; Tai, CL; Tobin, T; Weckman, TJ; Wood, T; Woods, WE, 1990
)
0.28
" According to the dose-response curves for isoproterenol and tyramine, left ventricular dP/dtmax was significantly depressed in infarcted hearts, whereas the dose-response curve for the inotropic effect of phenylephrine was markedly enhanced."( Defibrotide, an antithrombotic substance that preserves postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts.
Berti, F; Folco, G; Niada, R; Omini, C; Rossoni, G; Tondo, C,
)
0.37
" The following were the most significant effects of MDL 19205: a decrease in action potential duration in both ventricular and Purkinje tissues; a cumulative dose-dependent increase in contractile force in ventricular muscle but not in Purkinje strands; no change in aiNa in Purkinje fibers to accompany the positive inotropic effect of this agent; a shift in the dose-response relation by approximately fourfold in the presence of beta-adrenergic blockade with sotalol (10(-7) M); an enhancement of diastolic depolarization in Purkinje fibers resulting in automaticity that is accelerated by overdrive; and a potentiation of the positive inotropic effects of MDL 19205 by 8-bromo-cAMP (1 mM), indicating a potent phosphodiesterase inhibitory action of MDL 19205."( Effects of MDL 19205 (piroximone), a new cardiotonic agent, on electrophysiological, mechanical, and intracellular ionic characteristics of sheep cardiac tissues.
Wasserstrom, JA,
)
0.13
" Both hypotensive agents shifted the dose-response curve to NE to the right."( Effect of ketanserin and prazosin on blood pressure and cardiovascular reactivity to vasopressor agents during the development of two kidney-two clip renal hypertension in the conscious rat.
Basso, N; Kurnjek, M; Mikulic, L; Taquini, AC, 1989
)
0.28
" The absence of a depression of the maximum of the dose-response curve of ST 587 and the very moderate attenuation of the maximal B-HT 920-induced increase in diastolic blood pressure (BP) confirms the lack of major calcium entry blocking properties of R 56865 for alpha-adrenoceptor-activated calcium channels in vitro."( Interaction between R 56865 and alpha-adrenoceptors in the pithed rat.
Fruh, C; Koch, P; Peters, T; Schneider, J; Wilffert, B; Wilhelm, D,
)
0.13
" The cumulative dose-response curve of ergotamine (1-100 micrograms/kg) vasoconstrictor effects was partially inhibited to the same extent by prazosin (1 mg/kg) and yohimbine (0."( Effects of ergotamine on cardiovascular catecholamine receptors in the pithed rat.
Badia, A; Cuffi, L; Moron, A; Vila, E, 1988
)
0.27
"Blood pressure and heart rate responses to oral tyramine have been measured in healthy volunteers before and after administration of the selective monoamine oxidase B inhibitor selegiline at high dosage (30 mg/day)."( Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.
Glover, V; Goodwin, BL; Prasad, A; Sandler, M; Signy, M; Smith, SE, 1988
)
0.8
"The effect of single and repeated dosing of paroxetine on the in vivo noradrenaline uptake process, as determined by tyramine pressor response tests, was evaluated in normal healthy subjects."( A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test.
Hassan, SM; Turner, P; Wainscott, G, 1985
)
0.72
" The dose-pressor responses, determined from the incremental elevation of systolic blood pressure, were unchanged in each of the three dosing intervals."( Pressor responses to tyramine and norepinephrine after subchronic administration of fluoxetine to man.
Bowsher, DJ; Farid, NA; Lemberger, L; Rowe, H; Tenbarge, JB, 1988
)
0.59
" With the bolus method, in contrast to the infusion procedure, the dose-response relationship was obvious in most subjects."( Evaluation of methods of administering tyramine to raise systolic blood pressure.
Dabice, JA; Givens, SV; Pace, DG; Reele, SB; Rogers-Phillips, CA; Rozik, LM, 1988
)
0.54
" During dosing with amiflamine or placebo, no subject tolerated 400 mg oral tyramine and no difference between the two regimens was found with regard to tyramine response."( Pressor response of oral tyramine in healthy men given amiflamine and placebo.
Alván, G; Graffner, C; Grind, M; Gustafsson, LL; Helleday, J; Lindgren, JE; Ogenstad, S; Selander, H; Siwers, B, 1986
)
0.8
" In the pretreatment experiment, dogs were dosed with amiflamine (3."( The effects of amiflamine, a reversible MAO-A inhibitor, on the first pass metabolism of tyramine in dog intestine.
Davies, DS; Dollery, CT; Kiuchi, Y; Oguchi, K; Yasuhara, H, 1986
)
0.49
" Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO."( Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
Huston, V; Marwood, JF; Wall, KT,
)
0.37
" On the other hand, the dose-response curve for tyramine shifted to the right in a parallel manner, and histamine-induced vasoconstriction was markedly potentiated by prolonged cold storage in a maximal increase in perfusion pressure."( Effects of prolonged cold storage on the responsiveness of isolated and perfused canine intermediate auricular artery.
Chiba, S; Ito, T, 1985
)
0.52
" The shifted dose-response curve was not parallel to the original."( Modification by prostaglandin E 2 (PGE 2 ) of the response of guinea-pig isolated vasa deferentia and atria to adrenergic stimuli.
Bhagat, B; Dhalla, NS; Ginn, D; La Montagne, AE; Montier, AD, 1972
)
0.25
" PRC was very responsive to minor increases in circulating levels of epinephrine but a dose-response relationship was not seen."( Inhibitory effect of circulating norepinephrine on epinephrine-induced renin secretion.
Carvalho, JS,
)
0.13
" It is concluded that in clinical dosage mianserin is devoid of effects upon muscarinic receptors, alpha 1 adrenoceptors and noradrenaline uptake in the pupil."( Failure of mianserin to affect autonomic function in the pupils of depressed patients.
Checkley, S; Delgado, I; Shur, E, 1983
)
0.27
"5 ng/ml of tyramine in 1 ml of human plasma and is thus suitable for monoamine oxidase inhibitor studies involving oral dosing with tyramine."( Measurement of tyramine in human plasma, utilising ion-pair extraction and high-performance liquid chromatography with amperometric detection.
Brown, MJ; Causon, RC, 1984
)
1.01
" In vivo dose-response curves obtained with the common substrates DA and p-TA showed approximately 20% deamination by the B enzyme."( Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
Azzaro, AJ; Schoepp, DD, 1981
)
0.26
" Dose-response curves were plotted with 1n-dose on the x-axis and percent of maximum change in TPR on the y-axis, and the following indices of responsiveness were used: slope, 1nED50, 1nx-intercept, and maximum response."( Increased systemic vascular responsiveness to catecholamines in spontaneously hypertensive rats.
Walsh, GM, 1983
)
0.27
"Responses of blood pressure and plasma catecholamines to intravenous injection of tyramine at increasing dosage (30, 45, and 60 microgram/kg, respectively) were evaluated in 25 normal subjects and 20 patients with mild essential hypertension."( Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects.
Beretta-Piccoli, C; Bianchetti, MG; Meier, A; Minder, I; Weidmann, P, 1982
)
0.88
" These results are similar to those reported with the therapeutic dosage of other selective MAO-A inhibitors."( Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
Armand, P; Berlin, I; Caille, P; Durrieu, G; Fitoussi, S; Molinier, P; Patat, A, 1995
)
0.6
" After intravenous dosing of LMM-heparin the maximal concentration was lower using the heparin-tyramine bead assay compared with the anti-factor Xa coagulation assay."( Magnetic bead protamine-linked microtiter assay for detection of heparin using iodinated low-molecular-mass heparin-tyramine.
Casu, B; Guerrini, M; Harenberg, J; Heene, DL; Löhr, G; Malsch, R; Torri, G, 1995
)
0.72
" Furthermore, bradykinin did not modify the dose-response curves for added norepinephrine."( Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat.
Djokovic, A; Erdös, EG; Miletich, DJ; Minshall, RD; Rabito, SF; Vogel, SM; Yelamanchi, VP, 1994
)
0.29
" Dose-response analysis indicated an IC50 of 350 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MDA-MB-231 estrone sulfatase activity."( Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Hegde, PV; Li, PK; Selcer, KW, 1997
)
0.73
" tyramine pressor sensitivity during both moclobemide dosing regimens was enhanced 3 to 4-fold."( Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
Amrein, R; Dingemanse, J; Guentert, T; Oie, S; Ouwerkerk, M; Wood, N, 1998
)
1.21
" In the cold stored preparations, the dose-response curve for tyramine was shifted to the right in a parallel manner."( Effects of prolonged cold storage on double peaked vasoconstrictor responses to periarterial nerve stimulation in isolated canine splenic arteries.
Chiba, S; Yang, XP, 1999
)
0.54
" The maximal effect of the dose-response curve for Expar was prevented by the alpha1-adrenergic blocking agent prazosin at 10 nM and 30 nM concentration dependently."( Sympathomimetic effects of Parquetina nigrescens (Periplocaceae) extract in isolated portal vein smooth muscle.
Datté, JY; Tillement, JP; Ziegler, A, 1999
)
0.3
" Then, after washing out BK and lowering the stimulation intensity to mechanical threshold, a cumulative dose-response curve for added NE was generated, allowing the positive inotropic effects of neural stimulation (with or without BK) to be expressed in terms of an equivalent inotropic concentration of added NE ([NE(eq)])."( Augmented sympathetic response to bradykinin in the diabetic heart before autonomic denervation.
Dietze, GJ; Pietrzyk, Z; Rabito, SF; Vogel, S, 2000
)
0.31
" The dose-response curves to ACh were similar in patients and controls, with maximum values of 19."( Effects of chronic sympathectomy on vascular function in the human forearm.
Atkinson, JL; Charkoudian, N; Clark, ES; Dietz, NM; Dinenno, FA; Eisenach, JH; Fealey, RD; Joyner, MJ, 2002
)
0.31
" Dose-response curves were established for the increase in BP induced by tyramine (5-200 mg/kg) administered orally via a naso-pharyngeal tube."( Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Gorodetsky, E; Gross, A; Wang, RH; Weinreb, O; Weinstock, M; Youdim, MB, 2002
)
0.79
" TYR PD30 increased significantly with desipramine dosing (p<0."( Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Bieck, PR; Bymaster, FP; Chalon, SA; Granier, LA; Hirth, C; Joliat, MJ; Potter, WZ; Vandenhende, FR, 2003
)
0.32
" Bretylium and guanethidine depress the slopes of the dose-response curves for the pressor and nictitating membrane contracting effects of tyramine."( Comparison of bretylium and guanethidine: tolerance, and effects on adrenergic nerve function and responses to sympathomimetic amines.
BOURA, AL; GREEN, AF, 1962
)
0.44
" The pressor responses to tyramine and to phenethylamine declined slowly with repeated injection; the extent of tachyphylaxis induced by these amines depended on the dosage and on the frequency of injection."( TACHYPHYLAXIS TO SOME SYMPATHOMIMETIC AMINES IN RELATION TO MONOAMINE OXIDASE.
DAY, MD; RAND, MJ, 1963
)
0.54
" However irreversible MAO-A inhibitors continue to induce a cheese reaction, whereas MAO-B inhibitors at their selective dosage did not and led to introduction of L-deprenyl (selegiline) as an anti-Parkinson drug, since dopamine is equally well metabolized by both enzyme forms."( Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Weinstock, M; Youdim, MB, 2004
)
0.53
" The dose-response curves for tyramine were shifted to the right following treatment with dipyridamole (0."( Modification of transmitter release from periarterial nerve terminals by dipyridamole in canine isolated splenic artery.
Chiba, S; Naito, M; Yang, XP, 2004
)
0.61
" The dose of intravenous tyramine required to raise systolic blood pressure by 30 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/d dosage (P<0."( Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
Bieck, PR; Black, BK; Bymaster, FP; Garland, EM; Gonzales, C; Loghin, C; Potter, WZ; Robertson, D; Vincent, S, 2004
)
0.63
" Dosing of TCP and the use of multiple psychotropic comedications indicate a high-intensity treatment."( Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli, M; Bauer, M; Bschor, T; Janssen, G; Köberle, U; Pilhatsch, M; Ricken, R; Ulrich, S, 2008
)
0.35
"There is denervation supersensitivity in PD patients that is, however, insufficient to shift the dose-response curve to the left."( Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy.
Lipp, A; Low, PA; Sandroni, P, 2009
)
0.35
" Atenolol inhibited the increase in HR at a small dosage of higenamine but potentiated it at a higher dosage."( Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats.
Andersen, RJ; Jansakul, C; Mulvany, MJ; Praman, S; Williams, DE, 2012
)
0.38
"This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions."( The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012
)
0.79
" Normal dosage isocarboxazide may be prescribed for all patients because isocarboxazide is not metabolized through the CYP2D6 enzyme complex like most other antidepressants."( [The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression].
Brøsen, K; Krogh-Nielsen, L; Larsen, JK, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
neurotransmitterAn endogenous compound that is used to transmit information across the synapse between a neuron and another cell.
EC 3.1.1.8 (cholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tyraminesAralkylamino compounds which contain a tyramine skeleton.
monoamine molecular messengerA group of neurotransmitters and neuromodulators that contain one amino group that is connected to an aromatic ring by ethylene group (-CH2-CH2-). Monoamines are derived from the aromatic amino acids phenylalanine, tyrosine, histidine and tryptophan.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (18)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Amine Oxidase reactions419
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB212
Tyrosine Metabolism1657
Alkaptonuria1657
Hawkinsinuria1657
Tyrosinemia Type I1657
Disulfiram Action Pathway2366
Tyrosinemia, Transient, of the Newborn1657
Dopamine beta-Hydroxylase Deficiency1657
Monoamine Oxidase-A Deficiency (MAO-A)1657
Isoquinoline Alkaloid Biosynthesis513
Tyrosine metabolism ( Tyrosine metabolism )2841
AtMetExpress overview0109
Tryptophan metabolism2342
Suberin biosynthesis022

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
dopamine D1 receptorHomo sapiens (human)Potency8.19950.00521.30228.1995AID624455
GLS proteinHomo sapiens (human)Potency8.97160.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency32.64270.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.13660.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.54040.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.93010.000817.505159.3239AID1159527; AID1159531
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.75190.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency12.58930.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
D(3) dopamine receptor isoform eHomo sapiens (human)Potency28.18380.02009.148539.8107AID720506
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.05010.00106.000935.4813AID943
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency31.62281.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
trace amine-associated receptor 1Homo sapiens (human)IC50 (µMol)0.88180.15713.82579.3940AID686984
Phenylethanolamine N-methyltransferaseBos taurus (cattle)Ki294.00000.00312.329310.0000AID155309
D(2) dopamine receptorHomo sapiens (human)Ki160.00000.00000.651810.0000AID63227
D(1A) dopamine receptorHomo sapiens (human)Ki390.00000.00010.836310.0000AID63040
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)0.17770.06852.11849.9700AID686985
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd8.51140.00042.58328.5114AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd8.51140.00012.62198.5114AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd8.51140.00012.29338.5114AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd8.32200.00042.47358.5114AID3169; AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd8.51140.00012.70068.5114AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd8.51140.00082.62148.5114AID6406
5-hydroxytryptamine receptor 3AHomo sapiens (human)EC50 (µMol)26.00000.00100.65503.8000AID330729
Beta-secretase 1Homo sapiens (human)Kd2,000.00000.04000.04000.0400AID318154
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd8.51140.02342.74218.5114AID6406
Trace amine-associated receptor 1Mus musculus (house mouse)EC50 (µMol)0.28000.00200.69705.4000AID1895499
Trace amine-associated receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.04950.01390.42632.0440AID1442356; AID1895498
Trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)0.59900.01501.41437.1900AID1813802; AID1895497; AID341210
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd8.51140.00082.62148.5114AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Activity107.00000.71005.30179.7000AID681117
D(1A) dopamine receptorHomo sapiens (human)KL390.00000.20600.70301.2000AID61998
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (196)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylase Bos taurus (cattle)
norepinephrine biosynthetic processDopamine beta-hydroxylase Bos taurus (cattle)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (51)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylase Bos taurus (cattle)
copper ion bindingDopamine beta-hydroxylase Bos taurus (cattle)
L-ascorbic acid bindingDopamine beta-hydroxylase Bos taurus (cattle)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylase Bos taurus (cattle)
transport vesicle membraneDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
secretory granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule membraneDopamine beta-hydroxylase Bos taurus (cattle)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (187)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID62000log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID125215Compound was evaluated as substrate for monoamine oxidase (MAO) from bovine erythrocyte and the enzymatic kinetic constant was reported as Kcat; d = Values not determined experimentally1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID429528Binding affinity to Mushroom tyrosinase assessed as compound turnover by HPLC analysis2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Dopamine- and tyramine-based derivatives of triazenes: activation by tyrosinase and implications for prodrug design.
AID637765Activity of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID1054224Activity at mushroom tyrosinase by Michaelis-Menten plot analysis2013European journal of medicinal chemistry, , Volume: 70Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
AID1136412Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID231141Ratio of the kinetic parameter Kcat to the Km on substrate dopamine beta-hydrolase from bovine adrenals1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID263688Inhibitory activity against tyrosinase at 100uM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase.
AID341210Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID637764Activity of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID330728Activity at SER3 receptor expressed in HEK293 cells assessed as increase in calcium at 10 uM by calcium imaging assay2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID62284Kinetic parameter kcat was measured for dopamine beta-monooxygenase1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
The enantiomeric specificity of the antihypertensive activity of 1-(phenylthio)-2-aminopropane, a synthetic substrate analogue for dopamine beta-monooxygenase.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID175509Displacement of specifically bound [3H]naloxone from rat brain homogenate, in the absence of NaCl1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Novel analogues of enkephalin: indentification of functional groups required for biological activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID774310Antiprotozoal activity against clinical isolates of Entamoeba histolytica HM-1:IMSS2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Hydroxyclerodanes from Salvia shannoni.
AID1895499Agonist activity at mouse TAAR1 stably expressed in HEK293 cells incubated for 30 mins by cAMP assay2021Journal of natural products, 08-27, Volume: 84, Issue:8
The Alkaloids from
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID1813803Agonist activity at recombinant human TAAR1 expressed in CHO-K1 cells assessed as maximal increase in intracellular cAMP incubated for 30 mins by HTRF analysis relative to control2022ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
AID62283Kcat/Km value of the compound1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
The enantiomeric specificity of the antihypertensive activity of 1-(phenylthio)-2-aminopropane, a synthetic substrate analogue for dopamine beta-monooxygenase.
AID61992Compound was evaluated as substrate for Dopamine beta hydroxylase (DBH) from bovine adrenals and the enzymatic kinetic constant was reported as Kcat1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID1066372Activation of mouse TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID63040Affinity towards Dopamine receptor D11998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID73710Displacement of specifically bound [3H]naloxone from guinea pig ileum, in the presence of 100 mM NaCl1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Novel analogues of enkephalin: indentification of functional groups required for biological activity.
AID229309Ratio of IC50 compared to [D-Ala2, D-Leu5]-enkephalin in guinea pig ileum assay1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Novel analogues of enkephalin: indentification of functional groups required for biological activity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID62282Kinetic parameter Km was measured for dopamine beta-monooxygenase1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
The enantiomeric specificity of the antihypertensive activity of 1-(phenylthio)-2-aminopropane, a synthetic substrate analogue for dopamine beta-monooxygenase.
AID62142Compound was evaluated as substrate for Dopamine beta hydroxylase (DBH) from bovine adrenals and the enzymatic kinetic constant was reported as Km1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID6409Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities.
AID1066373Activation of rat TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to control2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID155309The compound was tested for In vitro inhibitory activity against Phenylethanolamine N-Methyltransferase (PNMT)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Conformationally restricted and conformationally defined tyramine analogues as inhibitors of phenylethanolamine N-methyltransferase.
AID215613Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly Beta adrenergic receptor was determined1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.
AID231144Ratio of the kinetic parameter Kcat to the Km on substrate dopamine monoamine oxidase; d = Values not determined experimentally1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID61998Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID125219Compound was evaluated as substrate for monoamine oxidase (MAO) from bovine erythrocyte and the enzymatic kinetic constant was reported as Km; d = Values not determined experimentally1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.
AID232381Relative EC50 compared to [D-Ala2, D-Leu5]-enkephalin without NaCl in rat brain assay1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Novel analogues of enkephalin: indentification of functional groups required for biological activity.
AID1442356Agonist activity at rat N-terminal FLAG-tagged TAAR1 expressed in HEK293 cells assessed as [3H]cAMP accumulation measured after 1 hr2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID774309Antiprotozoal activity against clinical isolates of Giardia lamblia IMSS:8901:12013Journal of natural products, Oct-25, Volume: 76, Issue:10
Hydroxyclerodanes from Salvia shannoni.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID678842TP_TRANSPORTER: uptake in OCT3-expressing HEK293 cells1998Nature neuroscience, Sep, Volume: 1, Issue:5
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.
AID341211Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay relative to 2-phenylethanamine2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID318154Binding affinity to BACE1 by surface plasmon resonance method2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Tyramine fragment binding to BACE-1.
AID681601TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells1998British journal of pharmacology, Sep, Volume: 125, Issue:1
Catecholamine transport by the organic cation transporter type 1 (OCT1).
AID330729Activity at SER3 receptor expressed in HEK293 cells assessed as increase in calcium by calcium imaging assay2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1895497Agonist activity at human TAAR1 stably expressed in HEK293 cells incubated for 30 mins by cAMP assay2021Journal of natural products, 08-27, Volume: 84, Issue:8
The Alkaloids from
AID77993Ability to Inhibit amplitude of the electrically stimulated guinea pig ileum by 50%; Inactive at 2.19E-4 concentration1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Novel analogues of enkephalin: indentification of functional groups required for biological activity.
AID63227Affinity towards Dopamine receptor D21998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID1895498Agonist activity at rat TAAR1 stably expressed in HEK293 cells incubated for 30 mins by cAMP assay2021Journal of natural products, 08-27, Volume: 84, Issue:8
The Alkaloids from
AID3169Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities.
AID378803Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 as parasite DNA microfluorimetric assay2006Journal of natural products, Oct, Volume: 69, Issue:10
Antiplasmodial metabolites isolated from the marine octocoral Muricea austera.
AID1813802Agonist activity at recombinant human TAAR1 expressed in CHO-K1 cells assessed as increase in intracellular cAMP incubated for 30 mins by HTRF analysis2022ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
AID1346375Human TA1 receptor (Trace amine receptor)2001Proceedings of the National Academy of Sciences of the United States of America, Jul-31, Volume: 98, Issue:16
Trace amines: identification of a family of mammalian G protein-coupled receptors.
AID1346295Mouse TA1 receptor (Trace amine receptor)2009The Biochemical journal, Oct-23, Volume: 424, Issue:1
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
AID1346375Human TA1 receptor (Trace amine receptor)2011PloS one, , Volume: 6, Issue:10
Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists.
AID1346295Mouse TA1 receptor (Trace amine receptor)2007Genes, brain, and behavior, Oct, Volume: 6, Issue:7
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia.
AID1346358Rat TA1 receptor (Trace amine receptor)2007The Journal of pharmacology and experimental therapeutics, Apr, Volume: 321, Issue:1
Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
AID1346375Human TA1 receptor (Trace amine receptor)2007The Journal of pharmacology and experimental therapeutics, Jan, Volume: 320, Issue:1
Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1.
AID1346375Human TA1 receptor (Trace amine receptor)2008Molecular pharmacology, Sep, Volume: 74, Issue:3
Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor.
AID1346375Human TA1 receptor (Trace amine receptor)2009The Biochemical journal, Oct-23, Volume: 424, Issue:1
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
AID1346358Rat TA1 receptor (Trace amine receptor)2009Proceedings of the National Academy of Sciences of the United States of America, Nov-24, Volume: 106, Issue:47
The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.
AID1346295Mouse TA1 receptor (Trace amine receptor)2009Proceedings of the National Academy of Sciences of the United States of America, Nov-24, Volume: 106, Issue:47
The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.
AID1346358Rat TA1 receptor (Trace amine receptor)2001Molecular pharmacology, Dec, Volume: 60, Issue:6
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.
AID1346295Mouse TA1 receptor (Trace amine receptor)2007The Journal of pharmacology and experimental therapeutics, Apr, Volume: 321, Issue:1
Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
AID1346375Human TA1 receptor (Trace amine receptor)2009Proceedings of the National Academy of Sciences of the United States of America, Nov-24, Volume: 106, Issue:47
The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,588)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903588 (64.21)18.7374
1990's606 (10.84)18.2507
2000's572 (10.24)29.6817
2010's611 (10.93)24.3611
2020's211 (3.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.69 (24.57)
Research Supply Index8.70 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index156.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials164 (2.82%)5.53%
Reviews202 (3.47%)6.00%
Case Studies49 (0.84%)4.05%
Observational3 (0.05%)0.25%
Other5,405 (92.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Parallel Group Study in Healthy Subjects to Evaluate the Effect of Multiple Oral Doses of BI 1467335 and Phenelzine as Positive Control on Blood Pressure Response to Oral Tyramine (Double-blind, Randomised, Placebo-controlled Design for BI 14673 [NCT03979820]Phase 153 participants (Actual)Interventional2019-07-31Terminated(stopped due to Study discontinued - testing of highest dose obsolete)
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Evaluate the Effect of Ozanimod on Pressor Response to Oral Tyramine in Healthy Adult Subjects [NCT03694119]Phase 192 participants (Actual)Interventional2018-07-24Completed
The Pathophysiology of Orthostatic Hypotension [NCT00748059]Phase 110 participants (Actual)Interventional1996-12-31Completed
A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge [NCT01539473]Phase 130 participants (Actual)Interventional2012-02-29Completed
Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133) [NCT00203125]Phase 355 participants (Actual)Interventional2000-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03979820 (1) [back to overview]Tyramine Sensitivity Factor (TSF)

Tyramine Sensitivity Factor (TSF)

TSF was defined as ratio of the tyramine dose causing an increase of systolic blood pressure (SBP) ≥ 30 millimetre of mercury (mmHg) for at least 3 consecutive measurements (TYR30) at baseline and at steady state of BI 1467335, placebo or phenelzine. Geometric Mean is the Geometric Least Squares Mean and is extracted from the ANOVA model that includes all treatments. Standard error is the geometric standard error of the mean (gSE) and is extracted from the ANOVA model that includes all treatments. (NCT03979820)
Timeframe: "At baseline (Day -11 up to Day-2) and at steady state (Day 29 up to Day 39 for the Placebo/Placebo + Tyramine and 10 mg BI 1467335/10 mg BI 1467335 + Tyramine arms, Day 8 up to Day 19 for the Phenelzine/ Phenelzine + Tyramine arm)."

InterventionRatio of tyramine dose (Geometric Least Squares Mean)
Placebo/Placebo + Tyramine0.98
Phenelzine/Phenelzine + Tyramine5.31
10 mg BI 1467335/10 mg BI 1467335 + Tyramine1.20

[back to top]